Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPL304110 in advanced solid malignancies
NCT04149691Phase 1Completed
- Sponsor
- Celon Pharma S.A.
- Start
- Jul 2019
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CPL304110 in gastric cancer (GC), bladder cancer, non-small cell lung cancer (NSCLC) and 4 more, sponsored by Celon Pharma S.A. Primary endpoints: Maximum Tolerated Dose at 4 weeks and Safety profile at 4 weeks. Started Jul 2019; status: completed.
02
Drugs
CPL304110
03
Conditions
gastric cancer (GC)bladder cancernon-small cell lung cancer (NSCLC)cholangiocarcinoma (CCA)sarcoma
Beyond the preview
Go deeper on NCT04149691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04149691.